RecruitingNCT03549754
iCaReMe Global Registry
Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases
Sponsor
AstraZeneca
Enrollment
35,000 participants
Start Date
Feb 17, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Being 18 years or older
- Having type 2 diabetes, Hypertension, Heart Failure and/or chronic kidney disease
- Providing written informed consent to participate in the registry
Exclusion Criteria2
- Having a life-threatening co-morbidity with life expectancy below 1 year
- Participating in an interventional trial requiring informed consent
Locations(55)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03549754
Related Trials
Mind Your Heart-II
NCT054311921 location
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location